VIJAYA · NSE
Vijaya Diagnostic Centre Limited
₹1,572.3
+4.08% (+₹61.7)
Prev. close
₹1,510.6
Volume
5,38,498
Delivery %
16.6%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Sachin Gupta is bullish on Vijaya Diagnostic Centre, urging a buy at ₹1,534 with a target of ₹1,690 and stop‑loss at ₹1,…” | Sachin GuptaChoice Equity Broking | Vijaya Diagnostic Centre | PENDING | |
| “Bullish on Vijaya Diagnostic Centre, recommending a buy at ₹1060 with a target of ₹1136 and a stop loss at ₹1022. This c…” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | MISS | |
| “Recommends buying Vijaya Diagnostic Centre at ₹1020 with a target of ₹1100 and a stop loss at ₹980, identifying it as a …” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | MISS | |
| “Bullish on Vijaya Diagnostic Centre Ltd., recommending a buy at ₹1,060–1,090 with a target price of ₹1,280 in two to thr…” | Marketsmith India AnalysisMarketsmith India | Vijaya Diagnostic Centre Ltd. | MISS | |
| “Recommends buying Vijaya Diagnostic Centre at ₹1141.35, targeting ₹1222, with a stop loss at ₹1100, based on a breakout …” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | NOT TRIGGERED | |
| “Bullish on Vijaya Diagnostic Centre, recommending a buy at ₹1098 with a target of ₹1175 and a stop loss at ₹1060. This i…” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | MISS | |
| “Bullish on Vijaya Diagnostic Centre for the short term (2-3 weeks), recommending initiating long positions in the ₹1,010…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Vijaya Diagnostic Centre Ltd | MISS | |
| “Bullish on Vijaya Diagnostic Centre Ltd, recommending a buy around ₹960 with a stop loss at ₹945 for a target price of ₹…” | Ganesh DongreAnand Rathi | Vijaya Diagnostic Centre Ltd | MISS | |
| “Emkay Global Financial recommends buying Vijaya Diagnostic with a target price of ₹1150. The call is based on their anal…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Vijaya Diagnostic Centre Ltd | HIT | |
| “Recommends buying Vijaya Diagnostic Centre Ltd at ₹1072.7 with a stop loss at ₹1030 for a short-term target of ₹1150. Th…” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | MISS | |
| “Recommends buying Vijaya Diagnostic Centre at ₹1221.3, with a stop loss at ₹1177 and a target price of ₹1313. The stock …” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | MISS | |
| “Bullish on Vijaya Diagnostic Centre, recommending a buy at ₹1126.30 with a target of ₹1212 and a stop loss at ₹1085. Thi…” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | MISS | |
| “Recommends buying Vijaya Diagnostic Centre at ₹1,107.65 with a target of ₹1,188 and a stop loss at ₹1,070, adhering to a…” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | MISS | |
| “Recommends buying Vijaya Diagnostic Centre at ₹960, targeting ₹1020, with a stop loss at ₹925. This is presented as a br…” | Sumeet BagadiaChoice Equity Broking | Vijaya Diagnostic Centre Ltd | HIT |
Fundamentals
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, and molecular diagnostics; radiology services, such as CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, and gastroenterology; and advance radiology service comprising nuclear medicine, positron emission tomography CT, and MRI-3T services. It also provides health checkups and home sample collection services, as well as test services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Ms. Sura Suprita Reddy
Headquarters
Hyderabad
Employees
2,507
Website
vijayadiagnostic.comExchange
View on NSE ↗Key stats
Market cap
₹14,673.05 Cr
P/E ratio (TTM)
78.3
Dividend yield
0.14%
EPS (TTM)
₹18.19
Beta (1Y · daily vs NIFTY 50)
0.50
Beta (5Y · monthly vs NIFTY 50)
0.78
Shares float
4.90 Cr
EPS · quarter ended Jun 2026
₹5.15
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹462.37 Cr | ₹459.22 Cr | ₹547.81 Cr | ₹681.39 Cr | ₹814.20 Cr | |
EBITDA | — | ₹216.52 Cr | ₹196.18 Cr | ₹239.67 Cr | ₹290.51 Cr | ₹357.73 Cr |
| — | ₹109.68 Cr | ₹84.63 Cr | ₹118.83 Cr | ₹143.08 Cr | ₹172.98 Cr | |
Diluted EPS | — | ₹10.69 | ₹8.26 | ₹11.59 | ₹13.92 | ₹16.79 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹541.24 Cr | ₹713.46 Cr | ₹853.41 Cr | ₹982.75 Cr | ₹1,273.62 Cr | ₹1,507.05 Cr | |
| ₹141.05 Cr | ₹182.83 Cr | ₹247.56 Cr | ₹259.18 Cr | ₹319.58 Cr | ₹422.59 Cr | |
Stockholders' equity | ₹359.01 Cr | ₹468.22 Cr | ₹544.73 Cr | ₹657.19 Cr | ₹795.71 Cr | ₹957.15 Cr |
Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹158.00 Cr | ₹164.61 Cr | ₹183.30 Cr | ₹224.47 Cr | ₹270.59 Cr | |
Investing cash flow | — | ₹-123.06 Cr | ₹-109.57 Cr | ₹-142.31 Cr | ₹-181.87 Cr | ₹-174.22 Cr |
| — | ₹-30.57 Cr | ₹-41.91 Cr | ₹-44.55 Cr | ₹-52.05 Cr | ₹-69.49 Cr | |
Capital expenditure | — | ₹-122.35 Cr | ₹-124.84 Cr | ₹-87.96 Cr | ₹-95.55 Cr | ₹-182.72 Cr |
End cash position | ₹6.69 Cr | ₹11.05 Cr | ₹24.18 Cr | ₹22.25 Cr | ₹12.80 Cr | ₹39.68 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 22(3Q) | Jun 22 | Sep 22–Mar 23(3Q) | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.78% | 55.04% | 55.01% | 54.98% | 54.90% | 54.87% | 54.06% | 53.93% | 53.91% | 53.05% | 52.63% | 52.60% | 52.51% | 52.47% |
| Public | 45.22% | 44.96% | 44.99% | 45.02% | 45.10% | 45.13% | 45.94% | 46.07% | 46.09% | 46.95% | 47.37% | 47.40% | 47.49% | 47.53% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Vijaya Diagnostic Centre Limited | ₹14,944.97 Cr | ₹1,447.1 | 79.8 | 15.61 | 18.1% | 0.44 | +19.5% | +41.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.